Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

Sponsor
University of Luebeck
Study ID
NCT01269151
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lucentis (Ranibizumab) — DRUG
    Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry

Study Details

Multifocal-electroretinoram (ERG) and microperimetry are objective criteria to asses retinal function. No information besides visual acuity exist for the development of retinal function during the course of wet AMD during therapy with Lucentis. The aim of our study is to evaluate the value of multifocal-ERG and microperimetry as an sensitive tool and early predictor of recurrence of the disease. The second goal will be to evaluate the neuroprotective effects of an adequate therapy on retinal function using microperimetry and multifocal-ERG during the course of wet AMD.

Key Dates

First listed
Jan 4, 2011
Start date
Oct 31, 2010
Status verified
Apr 2015
Primary completion
Mar 31, 2013
Completion
Apr 30, 2014

Study Design

Enrollment
20 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Lucentis (Ranibizumab)

Primary Outcome Measure

Changes of retinal function of the macula monitored by multifocal-ERG and microperimetry as measured 12 months. [ Time Frame: 12 months ]

Related Studies